Alp Bugra Basat, MD
@AlpBugraBasat
Followers
2,981
Following
337
Media
203
Statuses
7,621
Biotech Executive and Physician - Scientist. No investment or medical advice intended. Views my own.
World
Joined March 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
FEMA
• 821609 Tweets
ORM BKK INTER CATWALK
• 355588 Tweets
jeonghan
• 253181 Tweets
True Way Of Worship
• 136119 Tweets
#AlwaysToYouHannie
• 96205 Tweets
#어디서라도부르자_정한아_생일축하해
• 95675 Tweets
SB19 LIVE
• 82995 Tweets
#アオのハコ
• 50784 Tweets
ダンダダン
• 39140 Tweets
Chagos Islands
• 27342 Tweets
Mauritius
• 27079 Tweets
#カリスマ3周年
• 23360 Tweets
ピッコロさん
• 22563 Tweets
Liz Cheney
• 22532 Tweets
Luis Carlos Vélez
• 22167 Tweets
$RDOG
• 19548 Tweets
首相方針
• 12415 Tweets
比例重複
• 12210 Tweets
原則公認
• 10122 Tweets
$BLUE today, 6-years after this tweet.
People look like totally ignoring leukemia risk with Lentiglobin. $BLUE
1
3
10
8
11
101
$XBI Just went thru the Stifel's Why Invest in Biotech? report. "Civilization" mentioned 29 times and "cash flow" mentioned just one time. To me, the tone sounds more like an invitation to a charity event than pitching an investment that can beat 5% FED benchmark with its cash
5
8
56
I think FDA is kindly telling $SRPT that they're not going to approve anything solely based on biological endpoints anymore. My take is eteplirsen was an exception and $SRPT should go with an NDA based on hard clinical endpoints (6MWT etc.) Tox & infection thing is ridiculous.
7
11
59
$VERV Oh boy.🤦♂️ "One patient dosed in the 0.45 mg/kg cohort experienced a myocardial infarction (Grade 3) the day after treatment. The event was considered potentially related to treatment due to the proximity to dosing."
11
12
44
Assuming that GLP1 drugs would evaporate NASH market is grossly underestimating the ability and willingness of people to eat junk food. I am not joking. Those drugs will simply give more room for junk food (metabolic credit) and it will be conveniently used up (like any credit).
13
7
40
Hot take: If tirzepatide and semaglutide mediated weight loss physiologically mimics exercise, this could be a huge deflationary wave in healthcare industry considering how obesity is directly linked to atherosclerosis, NASH, kidney failure, Alzheimer's and cancer. $XBI $LLY $NVO
17
4
39
$BMY entered the chat. $VKTX $MDGL $INSM $CYTK
BMS chief Boerner says company is still open to deals after spending more than $20B on M&A last year
0
11
26
4
6
35
$XBI Guess we have hit the rock bottom. If it goes below this, biotech would prove to be the baggiest bag in history.
5
1
30
Let's compare it to average surprise charge for an emergency room visit at Scripps.
It is outrageous that Merck is charging the government $700 per 5-pill pack of this drug. And that the US has not negotiated it down to a fair price.
by
@RebeccaDRobbins
That companies continue to gouge in the midst of a pandemic is unconscionable
48
106
391
3
1
27
$BIIB So you think aducanumab will be recommended by neuro guidelines and will be reimbursed by insurance easily?
If the FDA does not do its job, then someone else will do it for them.
1
3
25
$CYTK Question is really about safety profile when it comes to mavacamten vs aficamten. 7% of patients in the EXPLORER-HCM trial of mavacamten had systolic dysfunction which led to a boxed warning. Let's see if short half life of aficamten would do the trick. I think it will
0
3
25
"Ozempic overdose? Poison control experts explain why thousands OD’d this year"
3000 cases in 2023 and growing.
$EIGR got the only GLP1R antagonist which could be an antidote but the management busy dragging the company to bankruptcy.
0
3
23
If you bought $XBI around September 2015, you would be down ~3% as of today.
Impressive, very nice!
2
1
24
$XBI Took profits and back to 80% cash. Risk reward ratio has never been so unfavorable since 2021.
7
2
23
I've just made a bet on Tony Coles and bunch of Cell papers. Let's see how it pans out. $YMTX
4
2
23
$SLRN Looks like now we know the reason, they should make that CRO's name public:
"However, ACELYRIN’s protocol was programmed incorrectly by the vendor, resulting in a sequencing error that went further unidentified through the providers’ testing processes. As a result, some
Can someone explain me how you get placebo response in autoimmune diseases? $MLTX $SLRN
7
1
10
1
3
21
$XBI $IBB "Firms including San Francisco-based EcoR1 Capital, a rare biotech investor whose hedge funds have made money so far this year, are calling in cash from clients to put into newly cheap stocks, according to people familiar with the matter."
1
2
23
Not an IPO hater here but seriously wondering why $ANTX's fate would be different than $PRTK $NBRV $TTPH $MLNT $AKAO. Just asking a broad question here about antibiotic-focused biotech companies and their poor performance in the past. Paging
@PeterKolchinsky
9
5
21
$NVS to buy $KDNY for $40/share.
MW is short $KDNY. We believe its lead drug, atrasentan, will never get FDA approval. Trial data have shown it's a) inefficacious and b) increases cardiac and mortality risks. AbbVie and KDNY have manipulated and misrepresented trial data to conceal
10
17
69
1
2
22
$XBI $IBB Summary of a negative NPV industry:
"At an industry level, an estimated $50 billion to $60 billion is spent annually on failed oncology trials."
0
4
21
$INSM Brensocatib adjusted hazard ratio from Ph2 trial:
10mg group = adjusted HR of 0.58 (95% CI, 0.35 to 0.95) (P = 0.03)
25-mg group = adjusted HR of 0.62 (95% CI, 0.38 to 0.99) (P = 0.046)
On the safety side, incidence of dental and skin adverse events were higher with
4
4
21
$GILD and $RHHBY merger rumors. Not sure what to say.
8
2
21
$BIIB Now we know that Bayesian statatistics and adaptive trial design can cure Alzheimer's.
2
1
19
$WVE Ultrapure or stereopure doesn't always mean better activity. Another analogous example is about kinase inhibitors. Better target specificity doesn't always translate into superior efficacy. Sloppy inhibitors hitting multiple kinases can do better in clinic.
1
2
20
$AVTE Short answer is systemic exposure.
Long answer (and better) is that treprostinil is acting thru GPCR and causing quick vascular dilatation not only in pulmonary arteries but also in pulmonary veins, quickly reducing the wedge pressure. So, inhalation would provide enough
1
1
21
A company was struggling with clinical trial bills, almost losing $10,000,000 a month. I told the owner that AI will be transformational for this business and the company subscribed to ChatGPT. Now the company loses $10,000,020 a month. 😂
1
2
19
I think the craziest part of this story is activating HGF-MET pathway to treat Alzheimer's... $ATHA
4
2
18
A guy running a big fund once said $BIIB aducanumab FDA approval will encourage investment in neuro area. I am sure those sale numbers are inspirational. This circus will give headaches to whole industry for a pretty long time.
2
1
19
$GBT 154 patients and VOC was not statistically significant. And they say it increases Hb levels. Of course, anything that increases hemoglobin oxygen affinity, like GBT440 does (), increases Hb levels thru erythrocytosis. See here:
5
3
21
It looks like we're gonna be grilling $CVAC during Memorial weekend.
0
0
18
$DVAX too sad. You already have a great adjuvant and there are endless opportunities in vaccine area (imagine influenza A-B, S. Aureus or H. Pylori vaccine) but gambling on cancer was more appealing. Obsession with immuno-oncology really killed a lot of good projects imho.
1
1
17
$IRON Another one. Their thesis was not really backed by human genetics and here we go today.
$IRON Bitopertin blocks GlyT1, this is the human phenotype when GlyT1 is mutated:
No sideroblastic anemia, which means even if you block GlyT1, porphyrin synthesis is unaffected. Probably some other transporter provides glycine.
Watch out there.
0
1
5
0
0
18
$TSVT $BLUE Nick in the arena, cracking eggs.
Bluebird is laying an egg called $TSVT, an oncology company. Since Nick Leschly will be the CEO, this egg will crack before it hatches. Hope they prove me wrong. $BLUE
0
0
8
4
0
18
$PTLA $111M net revenue with mcap $1.1BN This is oversold imho.
3
1
17
$AMGN No data but lots of optimism, plus dumped their only oral version.
$GILD level naiveness need for $VKTX buyout for +$10BN.
$LLY $NVO will sail their ships until a rare but severe side effect emerges. Neuroendocrine GI cancer risk? Maybe.
8
0
17
The most time and money consuming part in drug development is clinical trial execution, particularly enrollment. Algos for med chem have been used for a long time and all AI hype is around chemistry. Go make AI to help me enroll 100 patients in one month, that would be something
Farid is trying to bring AI excitement back to reality.
$SDGR — founded in 1990 — has lived through many hype cycles & Farid sees genAI/LLMs as the latest:
“It’s really bad to be near the word magical in science. That scares me. The more overhype, the harder you fall.”
0
1
4
4
2
18
My opinion about $APLS short report: "There are a lot of dumb people on Wall Street."
2
0
18
$AMLX just got $EIGR's avexitide. Congrats to them and hope they can find a good indication for this legit drug.
"Ozempic overdose? Poison control experts explain why thousands OD’d this year"
3000 cases in 2023 and growing.
$EIGR got the only GLP1R antagonist which could be an antidote but the management busy dragging the company to bankruptcy.
0
3
23
1
3
18
$ALNY mcap $7.5BN, no efficacy so far, many adverse effects, again $7.5BN.
2
6
16
Pre-clinic clinical hold. But I'd rather call it IND rejection. If you don't get any notice from FDA 30 days after filing IND, you can proceed but $CRSP just got one. $CRSP $VRTX
0
0
17
$ALNY $BBIO Silencer won't do much to already accumulated TTR, but stabilizer will have an immediate impact on existing protein.
Panelist says surprised not to see quicker time to effect with a silencer vs stabiliser. (Dr Fontana, HeliosB PI, points out QOL measures did emerge v quickly). Defence here from all speakers is that these trials do not allow H2H comparisons.
#ESCCongress2024
$ALNY $BBIO
1
4
14
1
2
19
$GILD For some, it takes multibillion dollars and almost a decade to figure out. Now let's $PFE's card.
Targeting CD47 causes massive hemolysis in mice. Not an exciting target.
1
1
11
3
1
17
$XBI Gov't should strictly regulate drug prices. And in response to crashing biotech stocks (due to drug price regulations), FED should start a biotech asset purchase program. Gov't can then make drugs free and FED will own all biotech companies. Smart, ha?🤪🤪
2
1
17
$SRPT Not a home run, but delandistrogene moxeparvovec clearly works.
2
0
17
CD40L inhibition is legit but for whatever the reason $ELDN is simply ignored by the market. Maybe the indication but still...
In a phase 2 trial involving participants with multiple sclerosis, the CD40L inhibitor frexalimab reduced the accumulation of new lesions on MRI at week 12 of treatment. Read the full trial results:
3
31
120
1
1
17
$XBI Called the top. Many of those PIPEs might stay underwater for quite sometime. But following Tiktok investors another option too. 😂
$XBI Took profits and back to 80% cash. Risk reward ratio has never been so unfavorable since 2021.
7
2
23
1
3
17
Sell $LLY, buy $PFE. I am a believer in $SGEN boost.
$pfe 52-week low. Is the market skeptical that $SGEN will plug its revenue hole in 2030?
3
1
7
8
1
16
“There are a lot of dumb people on Wall Street.” — Behzad Aghazadeh
Congrats to the $IMMU team and shareholders!
1
2
16
$ROIV Greatest flip of all times but the stonk is down.
1
1
16
Rest in piece legend...
3
0
16
Ahem. So, here is for $BBIO
Across the silent plains at dawn's first light,
Constellations disappear, ceding to the sun's might.
Onward does the brave soul tread,
Ready to face what lies ahead.
Amidst the echoes of ancient lore,
Memories whisper from distant shore.
Invisible
2
0
15
The real bull case is here for $AMRN 🤪: "Fish oil supplements were associated in a dose-response manner with higher semen volume and total sperm count, larger testicular size, a higher calculated free testosterone to LH ratio, and lower FSH and LH levels"
2
3
15
Shorting $IRON, $AMLX and few other nanocap bioturds gave me beta independence. I don't care about rates and CPI anymore. There are very serious structural issues in this biotech industry that you can take advantage of and make profit. Not sure how long it lasts though.
3
0
15
What are the legit but oversold names due to $XBI rebalancing in your opinion? Don't talk your own book, only honest suggestions :)
12
0
15
If you are screaming your short or long thesis, it is probably not a solid thesis. Back to work. Wasted too much time here.
5
0
15
FTC prepares to sue to block $AMGN $HZNP merger.
3
6
15
$SRPT CRL for golodirsen published. Most striking part here:
“Please understand that your failure to initiate eteplirsen’s confirmatory study with due diligence is very concerning to FDA and is of concern to the public.”
1
2
15
🎯 High quality growth company is NOT a biotech company, unfortunately. Some significant changes desperately needed. Maybe a total new model for biotech.
@BowTiedBiotech
Biotech is not our thing. It needs to be a high quality growth company with a proven business model.
8
0
33
4
2
15
Why do RNAi companies keep the garbage for themselves but give away golden eggs? Referring to $IONS $BIIB (nusinersen) and $ALNY $MDCO (inclisiran).
9
1
15
$ICPT Not a total bust, but fibrosis thing clearly surprised me. I was prepared for something even worse. But with that itch and LDL thing, this will never be a blockbuster.
3
5
14
$RUBY Pre-clinical, radical idea and $2BN valuation. What could go wrong?
1
3
14
$OCUL Never mind.
$OCUL Can someone explain me $1.4 BN valuation with 17M 2020 revenue? Never mind $26M of "selling and marketing" cost.
8
0
10
2
0
14
@federalreserve
@USTreasury
@FDICgov
Y'all wanted a recession to fight inflation and now we have one. So?
2
0
12
Does anybody know the PR company $RXRX hired? Seems like it is worth every penny.😂
2
1
14
$RUBY Literally everything could go wrong.
$RUBY Pre-clinical, radical idea and $2BN valuation. What could go wrong?
1
3
14
0
1
14
$LLY $NVO Wait for GPCR desensitization over the long run and this muscle to fat transition happens while on drug.
Hope I am wrong, but it's a likely scenario from what we know about GPCRs like GLP-1R. Read more here:
2
2
13
Mr. Soriot is a legend who made a fortune for $AZN investors and his 23M salary is being questioned while some clown microcap CEOs were getting away with close to $100M compensation over the years of failure.
AstraZeneca CEO's 2024 pay proposal under fire from influential proxy advisers
1
0
4
2
1
14
It looks like we are now canceling the patents today. No limits for cancelling. This will continue until the cancel culture eventually cancels the cancelling. Seriously, such a toxic ideology will eat itself sooner or later. $XBI $IBB
0
0
12
$AVTE Inhaled drugs end up first in alveoli, then in pulmonary capillaries and then eventually pulmonary veins. Probably zero exposure of pulmonary arteries. Interesting re-formulation, thou not sure what they were thinking😜
Looks like imatinib doesn't work in alveoli. How surprising. $AVTE
0
0
6
6
0
14
Gotta get that 6 pounds of broccoli per day approved by FDA.
Your mom was right: Eat your Broccoli!
"Natural compound found in broccoli reawakens the function of potent tumor suppressor"
14
122
345
2
2
13
This $MRSN drug called Upifitamab Rilsodotin, upri, XMT-1536 was eventually discontinued. It had 34% ORR.
Do your own judgement for $CTMX, especially if you are having hard time understanding the market's reaction.
ORR is remotely related to OS, it does
5
0
14
Simply imagine the potential mcap if $SRPT didn't dive into gene therapy but instead leveraged its exon skipping platform for oncology by restoring the expression of tumor suppressors such as p53. Even 1-3% expression is probably sufficient to induce apoptosis.
1
1
13
$ESPR Bempedoic Acid / Ezetimibe is a good pre-PCSK9 combo in treatment algorithm. Cheap pill vs expensive injectable. $AMGN $REGN
0
3
11
Easy to blame $GILD, but few, very few people were skeptical of CD47 pathway back in 2015-2016.
3
0
12
$XBI Unpopular opinion: High drug prices are essentially to compensate for poor judgement, mismanagement, and gross incompetence at the C-suite and board.
2
0
13
That +7.6% $XBI is not healthy, watch out next 10 days.
3
0
12
Anyone ever reviewed $CRVS in detail? Adenosine things are total garbage but what I like is CPI-818, a covalent inhibitor of ITK. I think these folks will succeed with this one. $CRVS R&D team developed ibrutinib. CPI-818 could be an "ibrutinib" for T-cells. Let's see how it goes
4
0
13
I don't understand the logic behind re-proposing myeloid or lymphoid kinase inhibitors for pancreatic cancer. $INCY did it with JAK inhibitor and failed, again this time $ABBV Bruton's kinase inhibitor failed. Inhibiting B-cells doesn't even fit with immuno-oncology approach.
1
2
13
$LJPC Angiotensin II lowered 28-day mortality rate in patients with baseline APACHE II scores>30 : 28-day mortality was 51.8% (n = 58) for the GIAPREZA group compared to 70.8% (n = 65) for the placebo group (hazard ratio=0.62 [95% CI: 0.39, 0.98; p=0.037])
1
4
13
$FGEN $AKBA
"FibroGen's roxadustat holds promise for sickle cell disease"
Finally someone did it.
Punchline is that roxadustat should be investigated, especially for B-thalassemia and maybe for Sickle cell.
Enjoy your Saturday night drink!
1
0
6
4
1
13
@Biomaven
@BillAckman
Peter, in general, fund managers are concerned about ongoing polarization between the right and left. So they try to make odd and anti-mainstream views more visible so that their supporters of such odd views don't get even more radicalized, especially after being deplatformed or
7
0
13
Two biotech companies that I like and trading close to book values are $TARA and $AKBA Let's see how they do.
3
0
13
Novartis to acquire Gyroscope Therapeutics. And GT for more common diseases is now becoming a thing. Not sure if this is bullish or bearish for $APLS though.
IMHO, GT is very underutilized modality for oncologic and maybe even for severe rheumatologic indications. Not sure 5-10 companies working on the same GT approach for the same disorder is something sustainable. We have enough knowledge about vectors to expand their use widely.
0
0
1
5
2
12
Some interesting stats here regarding the initial impact of COVID19 on stock market:
Markets lost $10 TN of value in total.
~1000 cases in US = $1 BN loss per case
~125000 cases worldwide = $8M per case
Not sure if this is justified, but likely we're in uncontrolled fear area.
2
5
10
$MRK Genetics driven drug development will lead you to success.
1
2
12
$XBI Rate cuts are not relevant imo. The real catalyst is a deflationary environment that allows the rate cuts. AI doesn't seem to be having its deflationary effect, but a de-escalation with China and Russia could help. I am going to go all in on risk assets (biotech, for example
2
0
12
Your $SRPT model now should discount for longer clinical development timeline and also for the risk of translation of biological endpoint to a clinical one.
3
1
12
$VSTM Given previous experience with defactinib, I don't think it does anything. VS-6766 seems active, especially for MEK responsive patients. Worst case, a me-too MEK inhibitor that also inhibits RAF. Best case, a new agent for KRASG12V. Reality should be something in between.
1
1
11
$FGEN $AKBA Some biology. Now you know what other things stabilized HIFs can do before upregulating EPO (likely cause of MACE side effects). HIFs do a lot when stabilized, upregulating EPO is just one thing. Here is the comprehensive list:
1
0
12
@zipjet
If you or a loved one has held $BMYRT, you may to be entitled to financial compensation. 😂😂😂
Happy New Year to you too! :)
1
0
12
$BMEA Clinical hold for BMF-219 due to drug-induced hepatotoxicity. I guess this diabetes story is over.
3
0
12